Royalty Finance, the UCC and Issues of Recharacterization

Sponsor: BCLT & Gibson Dunn

In this three-part virtual series, BCLT & Gibson, Dunn & Crutcher have partnered issues originally raised in a Law 360 article written by Gibson Dunn attorneys, Todd Trattner and Ryan Murr, entitled How Biotech Cos. Can Utilize Synthetic Royalty Financing. Gibson Dunn attorneys explore, in depth, royalty finance, looking at synthetic royalties, the treatment of synthetics under the UCC, and the risks of a sale of a synthetic royalty being recharacterized as a loan in bankruptcy. The aim of this virtual speaker series is to educate biotechnology stake holders (investors, entrepreneurs, companies, and their attorneys) on best practices for monetizing and investing in a synthetic royalty so that they may embark on such transactions with greater certainty. For anyone with an interest in how modern biotechnology companies raise capital, this series will help you optimize your rights and reduce your risks. Don’t miss it!

---